Blend · Pen
Verified recordGlow Blend
$20070mg
A three-peptide blend for laboratory research into tissue repair, skin biology and connective-tissue signalling.
Current batchGLOW 003-017
Published resultVerified
EternaGen / CJCIPA 002-028Blend · Research use only
CJC-1295 + Ipamorelin
$130CAD
A two-peptide blend used to explore how different signals influence the body’s growth-hormone system.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
CJC-1295 + Ipamorelin, clearly explained.
A two-peptide blend used to explore how different signals influence the body’s growth-hormone system.
Overview
CJC-1295 and ipamorelin influence growth-hormone signalling through different pathways. Each has some early human research, but the combination, its long-term effects and meaningful health outcomes have not been established.
CJC-1295 is a long-acting analogue of growth-hormone-releasing hormone. Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Evidence for each molecule must be kept separate from evidence for the fixed blend.- Format
- Vial
- Available strengths
- 10mg
- Batch
- CJCIPA 002-028
- Purity
- 99.1%
Research at a glanceLimited early human evidence for the individual compounds; combination not established
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- Confirm in batch record
- Molecular formula
- Confirm in batch record
- Molecular weight
- Confirm in batch record
- Storage and handling
- Follow the handling conditions listed on the Certificate of Analysis and physical label.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- CJCIPA 002-028
- Purity
- 99.1%
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Growth-hormone and IGF-I response
Short CJC-1295 studies in healthy adults measured pharmacokinetics and sustained changes in circulating growth hormone and IGF-I.
Evidence so far: Early human pharmacologyQuestion 02
Gastrointestinal motility
A phase 2 ipamorelin trial after bowel resection studied time to a standardized meal and found no significant difference on key or secondary efficacy analyses.
Evidence so far: Negative proof-of-concept trialQuestion 03
The fixed combination
The individual studies do not test this CJC-1295 plus ipamorelin blend, its ratio, or long-term clinical outcomes.
Evidence so far: Combination evidence gapProposed mechanism
How researchers are investigating the mechanism.
CJC-1295 and ipamorelin act through different receptors upstream of growth-hormone signalling. Measuring growth hormone or IGF-I shows pharmacodynamic activity; it does not by itself establish a meaningful health outcome.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Two randomized, placebo-controlled ascending-dose CJC-1295 studies lasting 28 and 49 days
- What researchers saw
- Investigators reported dose-dependent increases in growth hormone and IGF-I in healthy adults.
- Why that is not the whole story
- Biomarker changes in short healthy-volunteer studies are not evidence of disease benefit or long-term safety.
Study 02Randomized phase 2 ipamorelin trial in 117 bowel-resection patients
- What researchers saw
- The publication reported no significant difference in its key or secondary efficacy analyses.
- Why that is not the whole story
- That hospital trial used intravenous ipamorelin and did not evaluate this blend or another route.
Evidence gaps
What remains unknown?
- No well-controlled clinical evidence was identified for the fixed CJC-1295 plus ipamorelin combination.
- Long-term endocrine, metabolic and cardiovascular outcomes for the combination are not established.
- Different CJC-1295 forms are not automatically interchangeable; molecular identity and formulation matter.
Primary sources
Check the original sources.
- Primary CJC-1295 studyTeichman et al. Randomized healthy-adult pharmacology studies. J Clin Endocrinol Metab. 2006. PMID 16352683.
- Primary ipamorelin studyBeck et al. Postoperative phase 2 proof-of-concept trial. Int J Colorectal Dis. 2014. PMID 25331030.
- Regulatory safety reviewU.S. FDA. Safety considerations for CJC-1295 and ipamorelin-related bulk substances.
Related products
Continue comparing.
Blend · Vial
Verified recordKlow Blend
$22080mg
A four-peptide blend for laboratory research spanning tissue, skin and inflammatory-signalling models.
Current batchKLOW 002-009
Published resultVerified